ANGPT2 and neoplasm: Previous studies have suggested that Ang-2 may contribute to resistance mechanisms to immune checkpoint therapy by enhancing tumor recruitment of monocytes and macrophages and by upregulating PD-L1 expression in tumor-associated macrophages [26].